Elsevier

Atherosclerosis

Volume 210, Issue 1, May 2010, Pages 199-201
Atherosclerosis

Short communication
Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes

https://doi.org/10.1016/j.atherosclerosis.2009.11.021Get rights and content

Abstract

Objective

To compare the short-term effects of rosuvastatin and simvastatin on insulin-resistance and endothelial dysfunction in middle-aged patients with type 2 diabetes and mild untreated dyslipidemia.

Methods and design

29 Subjects randomly assigned to rosuvastatin 20 mg/daily or simvastatin 20 mg/daily for 4 weeks. Following data collected both pre- and post-treatment: fasting glucose, lipids, hs CRP, TNF-alpha, insulin sensitivity measured with euglycemic–hyperinsulinemic clamp and flow-mediated dilation with brachial artery reactivity technique.

Results

Both treatments markedly reduced LDL cholesterol (p < 0.001 for both). Insulin sensitivity did not change from relative baseline values in both groups, as well as fasting glucose and adiponectin. Simvastatin significantly improved flow-mediated dilation (p < 0.01), to a greater extent than in patients taking rosuvastatin (p = 0.09). We found no association between flow-mediated dilation improvement, LDL reduction and changes in hs CRP levels.

Conclusion

In type 2 diabetic individuals rosuvastatin was less effective than simvastatin at improving endothelium-dependent vasodilation within one month, without affecting insulin-resistance, adiponectin levels and inflammation.

Introduction

Type 2 diabetes (T2D) is characterized by an increased risk of cardiovascular complications. Endothelial dysfunction (ED) represents an underlying event for vascular abnormalities observed in diabetic patients, closely related to insulin-resistance (IR). An impaired nitric oxide bioavailability leading to an abnormal vasodilation may actually be triggered by multiple intracellular mechanisms resulting from an impaired sensitivity of insulin-signalling [1].

Besides modifications in lipid profile, statins have been reported to exert beneficial vascular actions, including anti-inflammatory effects and the up-regulation of nitric oxide production [2]. Moreover, some authors have reported that an improvement in ED can occur within a short period of statin administration [3]. Accordingly, even in diabetes mellitus, statins have been demonstrated to ameliorate ED and oxidative stress [4], [5].

However, the effects of statins on IR are somewhat controversial in diabetic patients and it is particularly unclear whether statins can simultaneously ameliorate ED and have an effect on IR. In individuals with T2D both simvastatin and atorvastatin have been reported to improve IR [6] while, in a recent study, high-dose simvastatin administration for 8 weeks did not show any effects on insulin action [7]. In addition, to our knowledge no study has ever evaluated the effects of rosuvastatin on IR, a synthetic statin with an extremely powerful lipid-lowering action, in diabetic patients.

This background prompted us to focus on the short-term effects of rosuvastatin and simvastatin administration on clamp-assessed IR and ED in individuals with type 2 diabetes.

Section snippets

Study design and subjects

We designed a randomized, single blind, parallel, intervention study which was approved by the local Ethics Committee and registered as a clinical trial (NCT00854503). All subjects gave their own written informed consent. Eligibility criteria were as follows: (a) known duration of diabetes of 3–10 years; (b) age 40–60 years; (c) BMI < 30; (d) good glycemic control (HbA1c < 7.0%); (e) LDL levels > 2.58 mmol/l; (f) no history of cardiovascular, neoplastic or other systemic diseases. The only allowed

Experimental results

The effects of 4 weeks of treatment with simvastatin 20 mg/daily or rosuvastatin 20 mg/daily on lipid profile, glucose metabolism, endothelial function and inflammation markers are summarized in Table 1. At baseline evaluation, no differences in all the parameters considered were detected between groups, except for slightly lower HDL levels in group R. During treatment period no patients changed their dietetic or life-style habits and no variations in oral anti-diabetic therapy were made.

Discussion

This study examined the early effects of rosuvastatin 20 mg/daily and simvastatin 20 mg/daily on insulin-resistance and endothelial dysfunction in middle-aged patients with type 2 diabetes and untreated mild dyslipidemia. Both treatments did not affect insulin sensitivity, glucose control and inflammation within 4 weeks. In addition, besides a greater improvement in lipid profile, rosuvastatin was less effective than simvastatin at improving endothelium-dependent vasodilation.

Growing evidence

Conflict of interest

No conflict of interest, potentially prejudicing the impartiality of the research reported, concerns this manuscript.

Acknowledgements

The present study has been supported by grants from the Ministero della Salute 2007 (Davide Lauro—Elena Tremoli) and PRIN-COFIN 2004 from the Ministero dell’Istruzione, Università e Ricerca (Davide Lauro—Elmo Mannarino).

References (10)

There are more references available in the full text version of this article.

Cited by (39)

  • Endoscopic Solutions for Colorectal Anastomotic Leaks

    2022, Techniques and Innovations in Gastrointestinal Endoscopy
  • Impact of statins on ALI/ARDS: A meta-analysis

    2016, Pulmonary Pharmacology and Therapeutics
  • Does statin therapy reduce plasma VEGF levels in humans? A systematic review and meta-analysis of randomized controlled trials

    2015, Metabolism: Clinical and Experimental
    Citation Excerpt :

    Accordingly, apoptosis and reversion of neointimal thickening in vascular smooth muscle cells are induced by the lipophilic statins, but not by pravastatin [8]. Furthermore, lipophilic statins beneficially impact on markers of endothelial dysfunction and oxidative stress [53–55], and rosuvastatin was shown to be less effective than simvastatin in improving endothelium-dependent vasodilatation, despite its powerful lipid-lowering action [56]. It appears that at equipotent LDL-C lowering effects of lipophilic and hydrophilic statins, the former can exert more pronounced effects on endothelial dysfunction [53,55,56].

  • Endothelial dysfunction in conduit arteries and in microcirculation. Novel therapeutic approaches

    2014, Pharmacology and Therapeutics
    Citation Excerpt :

    This increases the levels of vascular BH4, and decreases eNOS uncoupling thus improving endothelial function by reducing ROS generation and increasing NO bioavailability in the human vascular endothelium (Antoniades et al., 2011). It has been proposed that treatment with statins attenuates the apoptosis of EPCs (Lavi et al., 2010) and increases their number in a dose-dependent way (Bellia et al., 2010; Hong et al., 2010). According to some reports, this increase is independent of the reduction in serum cholesterol levels induced by statins and is associated with the improvement of endothelial function (Pirro et al., 2009; Higashi et al., 2010).

View all citing articles on Scopus
View full text